JP2001502297A - 医薬用化合物 - Google Patents

医薬用化合物

Info

Publication number
JP2001502297A
JP2001502297A JP10511080A JP51108098A JP2001502297A JP 2001502297 A JP2001502297 A JP 2001502297A JP 10511080 A JP10511080 A JP 10511080A JP 51108098 A JP51108098 A JP 51108098A JP 2001502297 A JP2001502297 A JP 2001502297A
Authority
JP
Japan
Prior art keywords
group
compound
alkyl
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10511080A
Other languages
English (en)
Japanese (ja)
Inventor
アル―アウォー，リマ・エス
エールハート，ウィリアム・ジェイ
ゴットゥムッカラ，サバラジュ・ブイ
マルティネリ，マイケル・ジェイ
モーアー，エリック・ディ
ムーア，リチャード・イー
マンロー，ジョン・イー
ノーマン，ブライアン・エイチ
ペイテル，ビノッド・エフ
シー，チュアン
トス，ジョン・イー
バスデバン，ベンカトラガバン
レイ，ジェイムズ・イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
University of Hawaii at Hilo
Original Assignee
University of Hawaii at Manoa
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1996/013855 external-priority patent/WO1997007798A1/en
Application filed by University of Hawaii at Manoa, Eli Lilly and Co filed Critical University of Hawaii at Manoa
Publication of JP2001502297A publication Critical patent/JP2001502297A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP10511080A 1996-08-30 1997-08-29 医薬用化合物 Pending JP2001502297A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US1996/013855 WO1997007798A1 (en) 1995-08-30 1996-08-30 Pharmaceutical compounds
US3898997P 1997-02-26 1997-02-26
US60/038,989 1997-02-26
US3952997P 1997-03-03 1997-03-03
US96/13855 1997-03-03
US60/039,529 1997-03-03
PCT/US1997/015245 WO1998008506A1 (en) 1996-08-30 1997-08-29 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
JP2001502297A true JP2001502297A (ja) 2001-02-20

Family

ID=27365489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10511080A Pending JP2001502297A (ja) 1996-08-30 1997-08-29 医薬用化合物

Country Status (5)

Country Link
EP (1) EP0957912A1 (https=)
JP (1) JP2001502297A (https=)
AU (1) AU4330097A (https=)
CA (1) CA2263420A1 (https=)
WO (1) WO1998008506A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69626544T2 (de) * 1995-12-22 2004-01-15 Lilly Co Eli Arzneistoffe
CA2264294A1 (en) * 1996-08-30 1998-03-05 University Of Hawai'i Process for preparing pharmaceutical compounds
HUP0000291A3 (en) * 1996-09-06 2000-10-30 Lilly Co Eli Process to prepare cryptophycin compounds
CA2264557A1 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process and novel intermediates
WO1998038178A1 (en) * 1997-02-26 1998-09-03 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
PL335478A1 (en) * 1997-02-26 2000-04-25 Lilly Co Eli Method of obtaining pharmaceutic compounds
US6180679B1 (en) * 1998-04-07 2001-01-30 Eli Lilly And Company Method for treating fungal infections
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN1764634A (zh) * 2003-01-22 2006-04-26 沃尼尔·朗伯有限责任公司 环丙基β－氨基酸衍生物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017093A1 (en) * 1993-12-21 1995-06-29 University Of Hawaii New cryptophycins
EP0850057A4 (en) * 1995-08-30 2001-04-11 Lilly Co Eli Pharmaceutical compounds
EP0792875B1 (en) * 1996-02-27 2001-05-09 Eli Lilly And Company Cryptophycin derivatives and their use as anti-microtubule agents

Also Published As

Publication number Publication date
EP0957912A1 (en) 1999-11-24
AU4330097A (en) 1998-03-19
CA2263420A1 (en) 1998-03-05
WO1998008506A1 (en) 1998-03-05
EP0957912A4 (https=) 1999-12-22

Similar Documents

Publication Publication Date Title
JP4364944B2 (ja) 医薬化合物群
JP2000501067A (ja) 医薬化合物
US6680311B1 (en) Cryptophycin compounds
JP2001502297A (ja) 医薬用化合物
US7173060B2 (en) Oxime derivatives and their use as pharmaceutically active agents
US8916573B2 (en) Quinazoline-2,4-dione derivatives
SA519402422B1 (ar) مركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
SK50793A3 (en) Method for preparing taxane derivatives, novel derivatives thereby obtained and pharmaceutical compositions containing same
KR20090097210A (ko) 키네신 방추체 단백질 (ｅｇ－５) 억제제로서의 이미다졸 유도체
JP4181632B2 (ja) 新規合成クリプトフィシン類
CA3080116A1 (fr) Derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SK572004A3 (en) New derivatives of oxazolidinones as antibacterial agents
JP5662940B2 (ja) 新規な抗微生物薬
JP2001500853A (ja) 医薬化合物
JP7737734B2 (ja) ピロール誘導体、その調製方法及びその用途
EP1482937A2 (en) Novel tyloindicines and related processes, pharmaceutical compositions and methods
US20020128185A1 (en) Pharmaceutical compounds
JP2002510625A (ja) Ｍｒｐ１の阻害方法
US6673809B2 (en) Tricyclic compounds as MRP1-inhibitors
KR20070095944A (ko) Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물 및조성물
JP2000502351A (ja) 医薬化合物
JPH09508917A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
JP6616525B2 (ja) Ｂａｃｅ１阻害剤
MXPA98001604A (en) Farmaceuti compounds
KR100505779B1 (ko) 제약 화합물